Milrinone in Congenital Diaphragmatic Hernia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

September 30, 2024

Study Completion Date

March 31, 2025

Conditions
Congenital Diaphragmatic HerniaPersistent Pulmonary Hypertension of the NewbornHypoxemic Respiratory FailurePulmonary Hypoplasia
Interventions
DRUG

Milrinone

The study intervention is an intravenous infusion of milrinone or placebo

DRUG

Placebo (5% Dextrose)

The study intervention is an intravenous infusion of milrinone or placebo

Trial Locations (19)

10032

Columbia University, New York

14642

University of Rochester, Rochester

19104

University of Pennsylvania, Philadelphia

27709

RTI International, Durham

27710

Duke University, Durham

30303

Emory University, Atlanta

35233

University of Alabama at Birmingham, Birmingham

43205

Research Institute at Nationwide Children's Hospital, Columbus

44106

Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland

45267

Cincinnati Children's Medical Center, Cincinnati

52242

University of Iowa, Iowa City

53226

Children's Hospital of Wisconsin, Milwaukee

64108

Children's Mercy, Kansas City

75235

University of Texas Southwestern Medical Center at Dallas, Dallas

77030

University of Texas Health Science Center at Houston, Houston

84108

University of Utah, Salt Lake City

87131

University of New Mexico, Albuquerque

94304

Stanford University, Palo Alto

02905

Brown University, Women & Infants Hospital of Rhode Island, Providence

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

NICHD Neonatal Research Network

NETWORK